View all IQVIA events

During this in-person session, we plan to discuss potential implications of the IRA on oncology R&D: examining unintended consequences, emerging impacts on development programs, implications for clinical stakeholders, and how these can be mitigated to ensure that patients continue to fully benefit from therapeutic innovation.

Contact Us